Apart from involving in collab-oration with Novartis on the...

The roots of UTC track back to UPenn, where our scientific founder Prof. ZHAO Yangbing was the director of T cell engineering lab, and co-founder Prof. LIU Xiaojun the deputy director. A pioneer in T cell therapy, ZHAO Yangbing’s past research also contributed the first two CAR-T therapies to be approved by FDA -Kymeriah and Yescarta.

Apart from involving in collaboration with Novartis on the research and development on CAR-T pipelines, ZHAO Yangbing has also co-founded Tmunity with his colleague Carl June. Tmunity is a bio-tech providing next-generation T-cell therapy to overcome TME challenges and it has raised over 200 million dollar from investors since inception.

Founded in Octber of 2019 in Shanghai by ZHAO Yangbing, LIU Xiaojun, and SONG Xiaodong, an ex-Pfizer and ex-J&J executive, UTC therapeutics is a pre-clinical biotech focusing on adoptive T cell therapy that overcomes tumor microenvironment inhabitation.

The roots of UTC track back to UPenn, where our scientific founder Prof. ZHAO Yangbing was the director of T cell engineering lab, and co-founder Prof. LIU Xiaojun the deputy director. A pioneer in T cell therapy, ZHAO Yangbing’s past research also contributed the first two CAR-T therapies to be approved by FDA -Kymeriah and Yescarta.

Apart from involving in collaboration with Novartis on the research and development on CAR-T pipelines, ZHAO Yangbing has also co-founded Tmunity